Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of … Read more
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) - Total Assets
Latest total assets as of June 2025: NT$1.01 Billion TWD
Based on the latest financial reports, Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) holds total assets worth NT$1.01 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gwo Xi Stem Cell Applied Technology Co. , Ltd - Total Assets Trend (2019–2024)
This chart illustrates how Gwo Xi Stem Cell Applied Technology Co. , Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Gwo Xi Stem Cell Applied Technology Co. , Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Gwo Xi Stem Cell Applied Technology Co. , Ltd's total assets of NT$1.01 Billion consist of 29.1% current assets and 70.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 22.0% |
| Accounts Receivable | NT$13.20 Million | 1.2% |
| Inventory | NT$9.78 Million | 0.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$161.41 Million | 15.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Gwo Xi Stem Cell Applied Technology Co. , Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gwo Xi Stem Cell Applied Technology Co. , Ltd's current assets represent 29.1% of total assets in 2024, an increase from 3.5% in 2019.
- Cash Position: Cash and equivalents constituted 22.0% of total assets in 2024, up from 18.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, a decrease from 16.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 15.2% of total assets.
Gwo Xi Stem Cell Applied Technology Co. , Ltd Competitors by Total Assets
Key competitors of Gwo Xi Stem Cell Applied Technology Co. , Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Gwo Xi Stem Cell Applied Technology Co. , Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Gwo Xi Stem Cell Applied Technology Co. , Ltd generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Gwo Xi Stem Cell Applied Technology Co. , Ltd is currently not profitable relative to its asset base.
Gwo Xi Stem Cell Applied Technology Co. , Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.10 | 3.52 | 1.60 |
| Quick Ratio | 2.97 | 3.38 | 1.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$173.44 Million | NT$ 260.37 Million | NT$ 58.71 Million |
Gwo Xi Stem Cell Applied Technology Co. , Ltd - Advanced Valuation Insights
This section examines the relationship between Gwo Xi Stem Cell Applied Technology Co. , Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.45 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -13.4% |
| Total Assets | NT$1.06 Billion |
| Market Capitalization | $57.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gwo Xi Stem Cell Applied Technology Co. , Ltd's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Gwo Xi Stem Cell Applied Technology Co. , Ltd's assets decreased by 13.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Gwo Xi Stem Cell Applied Technology Co. , Ltd (2019–2024)
The table below shows the annual total assets of Gwo Xi Stem Cell Applied Technology Co. , Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.06 Billion | -13.38% |
| 2023-12-31 | NT$1.23 Billion | +17.31% |
| 2022-12-31 | NT$1.04 Billion | -3.95% |
| 2021-12-31 | NT$1.09 Billion | -7.47% |
| 2020-12-31 | NT$1.18 Billion | +11.04% |
| 2019-12-31 | NT$1.06 Billion | -- |